OMNIQ ANNOUNCES SUBMISSION OF APPLICATION TO OTCQX
May 08, 2024 16:15 ET
|
OMNIQ Corp.
SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) -- OMNIQ Corp. (OTC Pink: OMQS) (“OMNIQ” or “the Company”), a global leader in AI-based machine vision solutions for data processing and analytics,...
Opus One Gold Corporation Announces Private Placement of Up to $500,000
May 08, 2024 16:09 ET
|
Opus One Gold Corporation Inc.
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Opus One Gold Corporation (OOR: TSXV) (“Opus One Gold” or the “Company”), is pleased to announce a non-brokered private placement (the “Offering”) for...
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 08, 2024 16:06 ET
|
Context Therapeutics Inc.
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE...
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
May 08, 2024 16:05 ET
|
Pacira BioSciences
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate...
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 08, 2024 16:05 ET
|
Apollomics Inc.
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address...
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 08, 2024 16:01 ET
|
LENZ Therapeutics, Inc.
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 08, 2024 16:01 ET
|
Erasca, Inc.
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and...
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
May 08, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Safe & Green Holdings Reports Year-End 2023 Results
May 08, 2024 08:30 ET
|
Safe & Green Holdings Corp.
Reports 30% Increase in Construction Services Revenue Compared to 2022 Completed Successful Spin-Out of Safe and Green Development Corporation as a Nasdaq Listed Publicly Traded Company ...
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
May 08, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced...